Австралія - англійська - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - quetiapine fumarate, quantity: 57.565 mg (equivalent: quetiapine, qty 50 mg) - tablet, modified release - excipient ingredients: lactose monohydrate; iron oxide yellow; titanium dioxide; macrogol 400; povidone; light magnesium oxide; carrageenan; microcrystalline cellulose; magnesium stearate; iron oxide red - bipolar disorder - maintenance treatment of bipolar 1 disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes. treatment of depressive episodes associated with bipolar disorder (see dosage and administration). treatment of acute mania associated with bipolar i disorder as monotherapy or incombination with lithium or sodium valproate. efficacy of quetiapine in the treatment of bipolar disorder indications was established in part, on the basis of extrapolation from the established effectiveness of quetiapine immediate release tablets. schizophrenia - treatment of schizophrenia, prevention of relapse and maintenance of clinical improvement during continuation therapy. major depressive disorder (mdd)- treatment of recurrent major depressive disorde in patients who are intolerant of, or who have an inadequate response to alternative therapies. generalised anxiety disorder (gad). treatment of generalised anxiety disorder.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - quetiapine fumarate, quantity: 172.695 mg (equivalent: quetiapine, qty 150 mg) - tablet, modified release - excipient ingredients: titanium dioxide; magnesium stearate; microcrystalline cellulose; macrogol 400; lactose monohydrate; light magnesium oxide; carrageenan; povidone - bipolar disorder - maintenance treatment of bipolar 1 disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes. treatment of depressive episodes associated with bipolar disorder (see dosage and administration). treatment of acute mania associated with bipolar i disorder as monotherapy or incombination with lithium or sodium valproate. efficacy of quetiapine in the treatment of bipolar disorder indications was established in part, on the basis of extrapolation from the established effectiveness of quetiapine immediate release tablets. schizophrenia - treatment of schizophrenia, prevention of relapse and maintenance of clinical improvement during continuation therapy. major depressive disorder (mdd)- treatment of recurrent major depressive disorde in patients who are intolerant of, or who have an inadequate response to alternative therapies. generalised anxiety disorder (gad). treatment of generalised anxiety disorder.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - quetiapine fumarate, quantity: 230.26 mg (equivalent: quetiapine, qty 200 mg) - tablet, modified release - excipient ingredients: lactose monohydrate; magnesium stearate; iron oxide yellow; povidone; carrageenan; macrogol 400; light magnesium oxide; titanium dioxide; microcrystalline cellulose - bipolar disorder - maintenance treatment of bipolar 1 disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes. treatment of depressive episodes associated with bipolar disorder (see dosage and administration). treatment of acute mania associated with bipolar i disorder as monotherapy or incombination with lithium or sodium valproate. efficacy of quetiapine in the treatment of bipolar disorder indications was established in part, on the basis of extrapolation from the established effectiveness of quetiapine immediate release tablets. schizophrenia - treatment of schizophrenia, prevention of relapse and maintenance of clinical improvement during continuation therapy. major depressive disorder (mdd)- treatment of recurrent major depressive disorde in patients who are intolerant of, or who have an inadequate response to alternative therapies. generalised anxiety disorder (gad). treatment of generalised anxiety disorder.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - quetiapine fumarate, quantity: 460.52 mg (equivalent: quetiapine, qty 400 mg) - tablet, modified release - excipient ingredients: microcrystalline cellulose; magnesium stearate; povidone; macrogol 400; lactose monohydrate; light magnesium oxide; titanium dioxide; carrageenan - bipolar disorder - maintenance treatment of bipolar 1 disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes. treatment of depressive episodes associated with bipolar disorder (see dosage and administration). treatment of acute mania associated with bipolar i disorder as monotherapy or incombination with lithium or sodium valproate. efficacy of quetiapine in the treatment of bipolar disorder indications was established in part, on the basis of extrapolation from the established effectiveness of quetiapine immediate release tablets. schizophrenia - treatment of schizophrenia, prevention of relapse and maintenance of clinical improvement during continuation therapy. major depressive disorder (mdd)- treatment of recurrent major depressive disorde in patients who are intolerant of, or who have an inadequate response to alternative therapies. generalised anxiety disorder (gad). treatment of generalised anxiety disorder.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - quetiapine fumarate, quantity: 345.39 mg (equivalent: quetiapine, qty 300 mg) - tablet, modified release - excipient ingredients: magnesium stearate; macrogol 400; lactose monohydrate; light magnesium oxide; carrageenan; titanium dioxide; microcrystalline cellulose; iron oxide yellow; povidone - bipolar disorder - maintenance treatment of bipolar 1 disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes. treatment of depressive episodes associated with bipolar disorder (see dosage and administration). treatment of acute mania associated with bipolar i disorder as monotherapy or incombination with lithium or sodium valproate. efficacy of quetiapine in the treatment of bipolar disorder indications was established in part, on the basis of extrapolation from the established effectiveness of quetiapine immediate release tablets. schizophrenia - treatment of schizophrenia, prevention of relapse and maintenance of clinical improvement during continuation therapy. major depressive disorder (mdd)- treatment of recurrent major depressive disorde in patients who are intolerant of, or who have an inadequate response to alternative therapies. generalised anxiety disorder (gad). treatment of generalised anxiety disorder.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - quetiapine fumarate, quantity: 230.284 mg (equivalent: quetiapine, qty 200 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; povidone; sodium starch glycollate type a; magnesium stearate; calcium hydrogen phosphate dihydrate; microcrystalline cellulose; titanium dioxide; hypromellose; purified talc; macrogol 400 - quetiapine rbx tablets are indicated for: bipolar disorder = maintenance treatment of bipolar i disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes = treatment of depressive episodes associated with bipolar disorder (see dosage and administration) = treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate schizophrenia = treatment of schizophrenia

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - quetiapine fumarate, quantity: 28.785 mg (equivalent: quetiapine, qty 25 mg) - tablet, film coated - excipient ingredients: magnesium stearate; lactose monohydrate; calcium hydrogen phosphate dihydrate; povidone; sodium starch glycollate type a; microcrystalline cellulose; titanium dioxide; hypromellose; iron oxide yellow; iron oxide red; macrogol 400 - quetiapine rbx tablets are indicated for: bipolar disorder = maintenance treatment of bipolar i disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes = treatment of depressive episodes associated with bipolar disorder (see dosage and administration) = treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate schizophrenia = treatment of schizophrenia

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - quetiapine fumarate, quantity: 115.142 mg (equivalent: quetiapine, qty 100 mg) - tablet, film coated - excipient ingredients: magnesium stearate; microcrystalline cellulose; sodium starch glycollate type a; lactose monohydrate; calcium hydrogen phosphate dihydrate; povidone; titanium dioxide; hypromellose; purified talc; macrogol 400 - quetiapine rbx tablets are indicated for: bipolar disorder = maintenance treatment of bipolar i disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes = treatment of depressive episodes associated with bipolar disorder (see dosage and administration) = treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate schizophrenia = treatment of schizophrenia

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - quetiapine fumarate, quantity: 345.425 mg (equivalent: quetiapine, qty 300 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; calcium hydrogen phosphate dihydrate; sodium starch glycollate type a; microcrystalline cellulose; povidone; magnesium stearate; titanium dioxide; hypromellose; purified talc; macrogol 400 - quetiapine rbx tablets are indicated for: bipolar disorder = maintenance treatment of bipolar i disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes = treatment of depressive episodes associated with bipolar disorder (see dosage and administration) = treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate schizophrenia = treatment of schizophrenia

США - англійська - NLM (National Library of Medicine)

major pharmaceuticals - quetiapine fumarate (unii: 2s3pl1b6uj) (quetiapine - unii:bgl0jsy5si) - quetiapine 25 mg - quetiapine fumarate tablets are indicated for the treatment of schizophrenia. the efficacy of quetiapine in schizophrenia was established in three 6 week trials in adults. the effectiveness of quetiapine for the maintenance treatment of schizophrenia has not been systematically evaluated in controlled clinical trials. [see clinical studies (14.1)].    pediatric use information in patients (13 to 17 years of age) with schizophrenia is approved for astrazeneca pharmaceuticals lp’s quetiapine fumarate drug product labeling. however, due to astrazeneca pharmaceuticals lp’s marketing exclusivity rights; this drug product is not labeled for such use in those adolescent patients. quetiapine fumarate tablets are indicated for the acute treatment of manic episodes associated with bipolar i disorder, both as monotherapy and as an adjunct to lithium or divalproex. efficacy was established in two 12-week monotherapy trials in adults, in one 3-week adjunctive trial in adults, [see clinical studies (14.2) ]. quetiapine fum